# EDGAR Filing Document

**Accession Number:** 0001803737
**File Stem:** 0001803737-25-000148
**Filing Date:** 2025-8
**Character Count:** 89958
**Document Hash:** 8389495ed2beefbc577da5e764cc53c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001803737-25-000148.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001803737-25-000148

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 48

**CONFORMED PERIOD OF REPORT**: 20250806

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enhabit, Inc.
- **CENTRAL INDEX KEY:** 0001803737
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472409192
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41406
- **FILM NUMBER:** 251190062

**BUSINESS ADDRESS:**
- **STREET 1:** 6688 N. CENTRAL EXPRESSWAY, SUITE 1300
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75206
- **BUSINESS PHONE:** 4696216419

**MAIL ADDRESS:**
- **STREET 1:** 6688 N. CENTRAL EXPRESSWAY, SUITE 1300
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75206

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Encompass Health Home Health Holdings, Inc.
- **DATE OF NAME CHANGE:** 20200218

?xml version='1.0' encoding='ASCII'? ehab-20250806

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): August 6, 2025

**Enhabit, Inc.** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>001-41406</u>** | **<u>47-2409192</u>** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

**<u>6688 N. Central Expressway, Suite 1300, Dallas, Texas 75206</u>**

(Address of principal executive offices, including zip code)

**<u>(214) 239-6500</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.01 per share** | **EHAB** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02.** *Results of Operations and Financial Condition.\** 

On August 6, 2025, Enhabit, Inc. (the "Company") issued a press release reporting the financial results of the Company for the quarter ended June 30, 2025 (the "Earnings Press Release"). A copy of the Earnings Press Release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

**Item 7.01.** *Regulation FD Disclosure.\**

A copy of the supplemental information which will be discussed during the Company's earnings call at 10:00 a.m. Eastern Time on Thursday, August 7, 2025, is attached to this report as Exhibit 99.2 and incorporated herein by reference.

**Item 9.01.** *Financial Statements and Exhibits.*

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

---

| | |
|:---|:---|
| **<u>Exhibit Number</u>** | **<u>Description</u>** |
| <u>[99.1](q22025enhabitearningsrelea.htm)</u> | <u>[Earnings Press Release of Enhabit, Inc., dated August 6, 2025.\*](q22025enhabitearningsrelea.htm)</u> |
| <u>[99.2](enhabit_earningsxslidesx.htm)</u> | <u>[Supplemental information provided in connection with the](enhabit_earningsxslidesx.htm)[second](enhabit_earningsxslidesx.htm)[quarter 2025 earnings call of Enhabit, Inc.\*](enhabit_earningsxslidesx.htm)</u> |
| 104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document |

---

\* The information in Item 2.02 and 7.01, including Exhibit 99.1 and Exhibit 99.2, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| ENHABIT, INC. | ENHABIT, INC. | ENHABIT, INC. |
| By: | /s/ Dylan C. Black | /s/ Dylan C. Black |
|  | Name: | Dylan C. Black |
|  | Title: | General Counsel |

---

Dated: August 6, 2025

## Exhibit 99.1

**Exhibit 99.1**

![enhabit_hhhxlogoxverticalxa.jpg](enhabit_hhhxlogoxverticalxa.jpg)

**Enhabit Reports Second Quarter 2025 Financial Results**

***Company Increases Full-Year 2025 Guidance***

***Company to host a conference call tomorrow, August 7, 2025, at 10 a.m. EDT***

DALLAS, TX – August 6, 2025 – Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the second quarter ended June 30, 2025.

"Our second quarter results reflect strong execution of our strategic 2025 priorities, with sequential and year-over-year growth in revenue and Adjusted EBITDA," said Barb Jacobsmeyer, president and CEO of Enhabit. "Home health continued to benefit from our payer contract initiatives as admissions grew 1.3% year over year and saw further stabilization in Medicare Fee-for-Service census. Hospice delivered its sixth consecutive quarter of growth with average daily census rising 12.3% year over year. We also strengthened our balance sheet by reducing bank debt and increasing liquidity. With this momentum, we're well positioned for success in the second half of 2025."

**QUARTERLY PERFORMANCE - CONSOLIDATED**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net service revenue of $266.1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income attributable to Enhabit, Inc. of $5.2 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $26.9 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Earnings per share of $0.10

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted earnings per share of $0.13

**RECENT COMPANY HIGHLIGHTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home health non-Medicare admissions increased 5.2% with total admissions growth of 1.3% year over year; 2.0% growth when normalized for branches closed in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home health delivered its second straight quarter of net service revenue and Adjusted EBITDA growth while continuing to stabilize Medicare average daily census (ADC).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home health total ADC sequential growth of 2.1% and growth of 0.5% compared to the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home health cost per patient day remained flat year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice ADC increased 12.3% year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ ADC increased sequentially every quarter since Q1 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice admissions increased 8.7% year over year; 10.0% when normalized for branches closed in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice Adjusted EBITDA increased 53.8% year over year.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice cost per patient day increased 1.0% year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Adjusted EBITDA grew 6.7% year over year and 1.2% sequentially to $26.9 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Opened three de novo locations: One home health and two hospice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consistent de-levering of balance sheet with the fifth straight quarter of debt prepayment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Reduced bank debt by $10.0 million in the quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Prepayments totaling $45 million since Q1 2024 - lowering interest expense by $3.2 million over the same period.

**FINANCIAL RESULTS**

**Consolidated**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Q2** | **Q2** | **Q2** | **Q2** | **'25 vs. '24** |
| ***($ in millions, except per share data)*** | **2025** | **2025** | **2024** | **2024** | **'25 vs. '24** |
| Home health net service revenue | $205.9 | $205.9 | $210.2 | $210.2 | *(2.0)%* |
| Hospice net service revenue | 60.2 | 60.2 | 50.4 | 50.4 | *19.4%* |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total net service revenue** | **$266.1** | **$266.1** | **$260.6** | **$260.6** | ***2.1%*** |
|  | *% of revenue* |  | *% of revenue* |  |  |
| Cost of service | *50.9%* | $135.5 | *50.6%* | $131.8 | *2.8%* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Gross margin* | *49.1%* | 130.6 | *49.4%* | 128.8 | *1.4%* |
| General and administrative expenses | *38.8%* | 103.2 | *39.5%* | 103.0 | *0.2%* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Total operating expenses* | *89.7%* | $238.7 | *90.1%* | $234.8 | *1.7%* |
| Net income attributable to noncontrolling interests | 0.5 | 0.5 | 0.6 | 0.6 |  |
| **Adjusted EBITDA**<sup>(1)</sup> | **$26.9** | **$26.9** | **$25.2** | **$25.2** | ***6.7%*** |
| &nbsp;&nbsp;&nbsp;&nbsp;***Adjusted EBITDA margin***<sup>(1)</sup> | ***10.1%*** | ***10.1%*** | ***9.7%*** | ***9.7%*** |  |
| **Net income (loss) attributable to Enhabit, Inc.** | **$5.2** | **$5.2** | **($0.2)** | **($0.2)** | ***2,700.0%*** |
| **Reported diluted EPS** | **$0.10** | **$0.10** | **$—** | **$—** | ***N/A*** |
| **Adjusted diluted EPS**<sup>(1)</sup> | **$0.13** | **$0.13** | **$0.07** | **$0.07** | ***85.7%*** |
| **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** |
| Stock-based compensation expense | $3.6 | $3.6 | $2.2 | $2.2 |  |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(2)</sup> | $1.4 | $1.4 | $4.8 | $4.8 |  |
| (1) See reconciliation of Non-GAAP to GAAP measures.<br>(2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. | (1) See reconciliation of Non-GAAP to GAAP measures.<br>(2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. | (1) See reconciliation of Non-GAAP to GAAP measures.<br>(2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. | (1) See reconciliation of Non-GAAP to GAAP measures.<br>(2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. | (1) See reconciliation of Non-GAAP to GAAP measures.<br>(2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. | (1) See reconciliation of Non-GAAP to GAAP measures.<br>(2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. |

---

------

**SEGMENT RESULTS**

**Home health**

---

| | | | |
|:---|:---|:---|:---|
| | **Q2** | **Q2** | **'25 vs. '24** |
| ***($ in millions)*** | **2025** | **2024** | **'25 vs. '24** |
| **Net service revenue:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Medicare | $116.0 | $121.7 | (4.7)% |
| &nbsp;&nbsp;&nbsp;Non-Medicare | 87.8 | 86.3 | 1.7% |
| &nbsp;&nbsp;Private duty<sup>(1)</sup> | 2.1 | 2.2 | (4.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Home health net service revenue** | **205.9** | **210.2** | **(2.0)%** |
| Cost of service | 107.2 | 106.9 | 0.3% |
| &nbsp;&nbsp;&nbsp;*Gross margin* | *47.9%* | *49.1%* |  |
| General and administrative expenses | 59.1 | 58.6 | 0.9% |
| Net income attributable to noncontrolling interests | 0.3 | 0.5 | (40.0)% |
| **Segment Adjusted EBITDA**<sup>(2)</sup> | **$39.3** | **$44.2** | **(11.1)%** |
| *% Segment Adj. EBITDA margin*<sup>(2)</sup> | *19.1%* | *21.0%* |  |
| **Operational metrics *(actual amounts)*** |  |  |  |
| **Medicare:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Admissions | **23138** | 24015 | (3.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recertifications | **15860** | 16639 | (4.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completed episodes | **38818** | 41620 | (6.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average daily census | **19931** | 20629 | (3.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits | **546877** | 597742 | (8.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits per episode | **14.1** | 14.4 | (2.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue per episode | **$2988** | $2924 | 2.2% |
| **Non-Medicare:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Admissions | **31774** | 30209 | 5.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recertifications | **14532** | 14587 | (0.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average daily census | **22191** | 21282 | 4.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits | **570424** | 581326 | (1.9)% |
| **Total:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Admissions | **54912** | 54224 | 1.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total admissions growth* |  |  | *1.3%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recertifications | **30392** | 31226 | (2.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total recertifications growth* |  |  | *(2.7)%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average daily census | **42122** | 41911 | 0.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits | **1117301** | 1179068 | (5.2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits per episode | **13.7** | 14.0 | (2.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost per visit | **$94.7** | $89.0 | 6.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue per patient day | **$53.7** | $55.1 | (2.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost per patient day | **$28.0** | $28.0 | —% |
| (1) Private duty represents long-term comprehensive hourly nursing medical care.<br>(2) See reconciliation of Non-GAAP to GAAP measures. | (1) Private duty represents long-term comprehensive hourly nursing medical care.<br>(2) See reconciliation of Non-GAAP to GAAP measures. | (1) Private duty represents long-term comprehensive hourly nursing medical care.<br>(2) See reconciliation of Non-GAAP to GAAP measures. | (1) Private duty represents long-term comprehensive hourly nursing medical care.<br>(2) See reconciliation of Non-GAAP to GAAP measures. |

---

------

**Hospice**

---

| | | | |
|:---|:---|:---|:---|
| | **Q2** | **Q2** | **'25 vs. '24** |
| ***($ in millions)*** | **2025** | **2024** | **'25 vs. '24** |
| **Net service revenue** | **$60.2** | **$50.4** | **19.4%** |
| Cost of service | 28.3 | 24.9 | 13.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;*Gross margin* | *53.0%* | *50.6%* |  |
| General and administrative expenses | 17.7 | 16.3 | 8.6% |
| Net income attributable to noncontrolling interests | 0.2 | 0.1 | 100.0% |
| **Segment Adjusted EBITDA**<sup>(1)</sup> | **$14.0** | **$9.1** | **53.8%** |
| *% Segment Adj. EBITDA margin*<sup>(1)</sup> | *23.3%* | *18.1%* |  |
| **Operational metrics *(actual amounts)*** |  |  |  |
| **Total admissions** | **3140** | 2888 | 8.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total admissions growth* |  |  | *6.2%* |
| **Patient days** | **359486** | 320026 | 12.3% |
| **Discharged average length of stay** | **103** | 108 | (4.6)% |
| **Average daily census** | **3950** | 3517 | 12.3% |
| **Revenue per patient day** | **$167.5** | $157.5 | 6.3% |
| **Cost per patient day** | **$78.7** | $77.9 | 1.0% |
| (1) See reconciliation of Non-GAAP to GAAP measures. | (1) See reconciliation of Non-GAAP to GAAP measures. | (1) See reconciliation of Non-GAAP to GAAP measures. | (1) See reconciliation of Non-GAAP to GAAP measures. |

---

**GUIDANCE**

The Company has updated its guidance as of August 6, 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| ***($ in millions, except per share data)***  | **2024 Actuals** | **2025 Previous Guidance** | **2025 Updated Guidance** | |  |  |  |
| ***($ in millions, except per share data)***  | **2024 Actuals** | **2025 Previous Guidance** | **2025 Updated Guidance** | **Net service revenue** | $1034.8 | $1,050 to $1,080 | $1,060 to $1,073 |
| **Adjusted EBITDA** | $100.1 | $101 to $107 | $104 to $108 |  |  |  |  |
| **Adjusted EPS** | $0.21 | $0.41 to $0.51 | $0.47 to $0.55 |  |  |  |  |

---

For additional considerations regarding the Company's 2025 guidance ranges, see the supplemental information posted on the Company's website at http://investors.ehab.com.

**CONFERENCE CALL INFORMATION** 

The Company will host an investor conference call at 10 a.m. EDT on August 7, 2025 to discuss its results for the second quarter of 2025. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/680483829. Following the call, a replay will be available on the Company's website at http://investors.ehab.com.

**ABOUT ENHABIT HOME HEALTH & HOSPICE**

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 249 home health locations and 114 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit <u>enhabit.com.</u>

------

**OTHER INFORMATION**

***Note regarding presentation and reconciliation of non-GAAP financial measures***

The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA Margin, Adjusted EPS, and Adjusted free cash flow. For 2025, the Company has modified its methodology of calculating Adjusted free cash flow to exclude the impact of unusual or nonrecurring items on cash income taxes and changes in working capital. The change was made to conform to the Adjusted free cash flow measure with the current definition used by management and the Board of Directors to manage cash flow and evaluate performance. Prior periods presented herein have been recast to conform with the new methodology.

The Company believes the non-GAAP financial measures are useful to investors because they facilitate evaluation of core business operating results over multiple periods unaffected by differences in unusual or nonrecurring items. See "Supplemental Non-GAAP Information" for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three and six months ended June 30, 2025, provides further information regarding "unusual or nonrecurring items that are not typical of ongoing operations," a reconciliation item in our Adjusted EBITDA and Segment Adjusted EBITDA calculations. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.

The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and professional fees and other costs or income related to items the Company believes to not be indicative of its ongoing operations. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

***Note regarding presentation of same-store comparisons***

The Company uses "same-store" comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

------

**Enhabit, Inc.**

**Condensed Consolidated Statements of Income**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| ***(in millions, except per share data)*** | **2025** | **2024** | **2025** | **2024** |
| Net service revenue | $**266.1** | $260.6 | $**526.0** | $523.0 |
| Cost of service, excluding depreciation and amortization | **135.5** | 131.8 | **265.7** | 266.0 |
| General and administrative expenses | **108.2** | 110.0 | **215.7** | 217.5 |
| Depreciation and amortization | **5.7** | 7.6 | **12.0** | 15.4 |
| &nbsp;&nbsp;&nbsp;Operating income | **16.7** | 11.2 | **32.6** | 24.1 |
| Interest expense and amortization of debt discounts and fees | **8.7** | 10.9 | **18.1** | 22.0 |
| Other income | **—** |  | **(19.3)** |  |
| &nbsp;&nbsp;&nbsp;Income before income taxes and noncontrolling interests | **8.0** | 0.3 | **33.8** | 2.1 |
| Provision for (benefit from) income taxes | **2.3** | (0.1) | **9.7** | 0.8 |
| &nbsp;&nbsp;&nbsp;**Net income** | **5.7** | 0.4 | **24.1** | 1.3 |
| Less: Net income attributable to noncontrolling interests | **0.5** | 0.6 | **1.1** | 1.3 |
| &nbsp;&nbsp;&nbsp;**Net income (loss) attributable to Enhabit, Inc.** | $**5.2** | $(0.2) | $**23.0** | $— |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | **50.6** | 50.1 | **50.7** | 50.1 |
| &nbsp;&nbsp;&nbsp;Diluted | **51.4** | 50.1 | **51.2** | 50.1 |
| **Earnings (loss) per common share:** |  |  |  |  |
| &nbsp;&nbsp;Basic earnings per share attributable to Enhabit, Inc. common stockholders | $**0.10** | $— | $**0.45** | $— |
| &nbsp;&nbsp;Diluted earnings per share attributable to Enhabit, Inc. common stockholders | $**0.10** | $— | $**0.45** | $— |

---

------

**Enhabit, Inc.**

**Condensed Consolidated Balance Sheets**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| ***(in millions)*** | **June 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| **Current assets:** | | |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**37.1** | $28.4 |
| &nbsp;&nbsp;&nbsp;Restricted cash | **1.8** | 1.9 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **158.5** | 149.2 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **8.1** | 13.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **205.5** | 192.7 |
| Property and equipment, net | **16.2** | 17.7 |
| Operating lease right-of-use assets | **51.7** | 52.8 |
| Goodwill | **900.0** | 900.0 |
| Intangible assets, net | **49.4** | 58.1 |
| Other long-term assets | **2.6** | 4.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $**1225.4** | $1226.0 |
| **Liabilities and Stockholders' Equity** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | $**22.4** | $22.8 |
| &nbsp;&nbsp;&nbsp;Current operating lease liabilities | **12.9** | 12.3 |
| &nbsp;&nbsp;&nbsp;Accounts payable | **11.5** | 6.7 |
| &nbsp;&nbsp;&nbsp;Accrued payroll | **36.6** | 37.1 |
| &nbsp;&nbsp;&nbsp;Accrued medical insurance | **7.6** | 5.5 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | **39.9** | 41.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **130.9** | 126.2 |
| Long-term debt, net of current portion | **456.9** | 492.6 |
| Long-term operating lease liabilities, net of current portion | **40.6** | 41.8 |
| Deferred income tax liabilities | **14.1** | 11.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | **642.5** | 672.1 |
| Commitments and contingencies |  |  |
| Redeemable noncontrolling interests | **5.0** | 5.0 |
| **Stockholders' equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Total Enhabit, Inc. stockholders' equity | **552.4** | 523.5 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | **25.5** | 25.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity** | **577.9** | 548.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and stockholders' equity** | $**1225.4** | $1226.0 |

---

------

**Enhabit, Inc.**

**Condensed Consolidated Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| ***(in millions)*** | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net income | $**24.1** | $1.3 |
| Adjustments to reconcile net income to net cash provided by operating activities— |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | **12.0** | 15.4 |
| &nbsp;&nbsp;&nbsp;Amortization of debt-related costs | **0.7** | 0.7 |
| &nbsp;&nbsp;&nbsp;Gain on sale of investment | **(19.3)** |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | **7.6** | 4.0 |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | **2.5** | (1.1) |
| &nbsp;&nbsp;&nbsp;Other | **0.1** | (0.1) |
| &nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions— |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **(9.3)** | (1.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | **5.8** | 5.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **4.9** | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll | **(1.1)** | (1.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | **0.5** | 3.5 |
| &nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | **28.5** | 26.9 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of property and equipment, including capitalized software costs | **(2.2)** | (2.5) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of investment | **21.0** |  |
| &nbsp;&nbsp;&nbsp;Other | **0.2** | 0.8 |
| &nbsp;&nbsp;&nbsp;**Net cash provided by (used in) investing activities** | **19.0** | (1.7) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Principal payments on debt | **(10.0)** | (10.0) |
| &nbsp;&nbsp;&nbsp;Payments on revolving credit facility | **(25.0)** | (10.0) |
| &nbsp;&nbsp;&nbsp;Principal payments under finance lease obligations | **(1.5)** | (1.8) |
| &nbsp;&nbsp;&nbsp;Distributions paid to noncontrolling interests of consolidated affiliates | **(1.0)** | (2.2) |
| &nbsp;&nbsp;&nbsp;Other | **(1.4)** | (0.8) |
| &nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | **(38.9)** | (24.8) |
| &nbsp;&nbsp;&nbsp;**Increase in cash, cash equivalents, and restricted cash** | **8.6** | 0.4 |
| &nbsp;&nbsp;&nbsp;**Cash, cash equivalents, and restricted cash at beginning of period** | **30.3** | 29.8 |
| &nbsp;&nbsp;&nbsp;**Cash, cash equivalents, and restricted cash at end of period** | $**38.9** | $30.2 |

---

------

**Enhabit, Inc.**

**Supplemental Non-GAAP Information**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Earnings Per Share to Adjusted Diluted Earnings Per Share** | **Reconciliation of Earnings Per Share to Adjusted Diluted Earnings Per Share** | **Reconciliation of Earnings Per Share to Adjusted Diluted Earnings Per Share** | **Reconciliation of Earnings Per Share to Adjusted Diluted Earnings Per Share** | **Reconciliation of Earnings Per Share to Adjusted Diluted Earnings Per Share** |
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| ***(actual amounts)*** | **2025** | **2024** | **2025** | **2024** |
| **Earnings per common share:** |  |  |  |  |
| **Diluted earnings per share attributable to Enhabit, Inc. common stockholders** | $**0.10** | $— | $**0.45** | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment and disposal of assets<sup>(1)</sup> | **—** |  | (0.29) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items that are not typical of ongoing operations<sup>(2)</sup> | **0.02** | 0.07 | 0.04 | 0.13 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax adjustments<sup>(3)</sup> | **0.01** |  | 0.04 | 0.01 |
| **Adjusted diluted earnings per share**<sup>(4)</sup> | $**0.13** | $0.07 | $**0.23** | $**0.14** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment in 2025 resulted from the sale of Medalogix investment.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

(3)&nbsp;&nbsp;&nbsp;&nbsp;Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation and the effect of a valuation allowance recorded against a portion of our deferred tax assets.

(4)&nbsp;&nbsp;&nbsp;&nbsp;Adjusted diluted earnings per share may not sum due to rounding.

------

**Enhabit, Inc.**

**Supplemental Non-GAAP Information**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** |
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** |
| **Net income** | $**5.7** | $**0.4** | $**24.1** | $**1.3** |
| Interest expense and amortization of debt discounts and fees | 8.7 | 10.9 | 18.1 | 22.0 |
| Provision for (benefit from) income taxes | 2.3 | (0.1) | 9.7 | 0.8 |
| Depreciation and amortization | 5.7 | 7.6 | 12.0 | 15.4 |
| Gain on sale of investment and disposal of assets<sup>(1)</sup> |  |  | (19.3) | (0.2) |
| Stock-based compensation | 3.6 | 2.2 | 7.6 | 4.0 |
| Net income attributable to noncontrolling interests | (0.5) | (0.6) | (1.1) | (1.3) |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(2)</sup> | 1.4 | 4.8 | 2.4 | 8.5 |
| &nbsp;&nbsp;&nbsp;**Adjusted EBITDA** | $**26.9** | $**25.2** | $**53.5** | $**50.5** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment in 2025 resulted from the sale of Medalogix investment.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

------

**Enhabit, Inc.**

**Supplemental Non-GAAP Information**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Income Before Income Taxes and Noncontrolling Interests to Segment Adjusted EBITDA** | **Reconciliation of Income Before Income Taxes and Noncontrolling Interests to Segment Adjusted EBITDA** | **Reconciliation of Income Before Income Taxes and Noncontrolling Interests to Segment Adjusted EBITDA** | **Reconciliation of Income Before Income Taxes and Noncontrolling Interests to Segment Adjusted EBITDA** | **Reconciliation of Income Before Income Taxes and Noncontrolling Interests to Segment Adjusted EBITDA** |
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** |
| **Income before income taxes and noncontrolling interests** | $**8.0** | $**0.3** | $**33.8** | $**2.1** |
| Non-segment general and administrative expenses | 27.8 | 32.9 | 55.5 | 63.4 |
| Interest expense and amortization of debt discounts and fees | 8.7 | 10.9 | 18.1 | 22.0 |
| Depreciation and amortization | 5.7 | 7.6 | 12.0 | 15.4 |
| Gain on sale of investment<sup>(1)</sup> |  |  | (19.3) |  |
| Stock-based compensation expense | 3.6 | 2.2 | 7.6 | 4.0 |
| Net income attributable to noncontrolling interests | (0.5) | (0.6) | (1.1) | (1.3) |
| &nbsp;&nbsp;&nbsp;**Total Segment Adjusted EBITDA** | $**53.3** | $**53.3** | $**106.6** | $**105.6** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Home Health** | **Home Health** | **Hospice** | **Hospice** | **Home Health** | **Home Health** | **Hospice** | **Hospice** |
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| Net service revenue | $205.9 | $210.2 | $60.2 | $50.4 | $406.5 | $423.4 | $119.5 | $99.6 |
| Labor | 98.1 | 97.3 | 17.6 | 15.5 | 192.4 | 197.1 | 34.4 | 30.7 |
| Supplies and pharmacy | 2.4 | 2.3 | 5.4 | 4.7 | 4.8 | 5.1 | 10.6 | 9.3 |
| Travel | 5.2 | 5.5 | 1.2 | 1.2 | 10.3 | 11.1 | 2.4 | 2.3 |
| Other cost of service | 1.5 | 1.8 | 4.1 | 3.5 | 3.1 | 3.5 | 7.7 | 6.9 |
| Total cost of service, excluding deprecation and amortization | 107.2 | 106.9 | 28.3 | 24.9 | 210.6 | 216.8 | 55.1 | 49.2 |
| General and administrative expenses | 46.8 | 47.7 | 14.5 | 13.3 | 93.5 | 96.4 | 28.6 | 26.2 |
| Other general and administrative expenses | 12.3 | 10.9 | 3.2 | 3.0 | 24.0 | 21.7 | 6.5 | 5.8 |
| Total general and administrative expenses | 59.1 | 58.6 | 17.7 | 16.3 | 117.5 | 118.1 | 35.1 | 32.0 |
| Net income attributable to noncontrolling interests | 0.3 | 0.5 | 0.2 | 0.1 | 0.8 | 1.1 | 0.3 | 0.2 |
| Segment Adjusted EBITDA | $39.3 | $44.2 | $14.0 | $9.1 | $77.6 | $87.4 | $29.0 | $18.2 |
| *Segment Adjusted EBITDA margin*<sup>(2)</sup> | *19.1 %* | *21.0 %* | *23.3 %* | *18.1 %* | *19.1 %* | *20.6 %* | *24.3 %* | *18.3 %* |

---

(1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment.

(2) Segment Adjusted EBITDA margin is defined as the ratio of Segment Adjusted EBITDA to segment net service revenue.

------

**Enhabit, Inc.**

**Supplemental Non-GAAP Information**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** |
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** |
| **Net cash provided by operating activities** | $**10.6** | $**9.6** | $**28.5** | $**26.9** |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(1)</sup> | 3.4 | 4.8 | 4.4 | 8.5 |
| Capital expenditures for maintenance | (1.9) | (0.7) | (2.2) | (2.5) |
| Other working capital adjustments<sup>(2)</sup> | (1.1) | (3.0) | (1.9) | (3.6) |
| Distributions paid to noncontrolling interests of consolidated affiliates | (0.1) | (2.2) | (1.0) | (2.2) |
| **Adjusted free cash flow** | $**10.9** | $**8.5** | $**27.8** | $**27.1** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

(2)&nbsp;&nbsp;&nbsp;&nbsp;For 2025 and going forward, adjusted free cash flow will exclude the cash impact of unusual and nonrecurring items from both cash income tax payments (refunds), net, and working capital and other. The 2024 calculations have been conformed to the current methodology, which has an impact $(1.9) million for both Q2 and the year-to-date period.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** |
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Gross margin as a percentage of revenue** | **49.1%** | **49.4%** | **49.5%** | **49.1%** |
| General and administrative expenses | (40.7)% | (42.2)% | (41.0)% | (41.6)% |
| Stock-based compensation | 1.4% | 0.9% | 1.4% | 0.8% |
| Noncontrolling interests | (0.2)% | (0.2)% | (0.2)% | (0.2)% |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(1)</sup> | 0.5% | 1.8% | 0.5% | 1.6% |
| **Adjusted EBITDA margin** | **10.1%** | **9.7%** | **10.2%** | **9.7%** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

------

**FORWARD-LOOKING STATEMENTS** 

This press release contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, our future financial performance, our projected business results, or our projected capital expenditures. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "targets," "potential," or "continue" or the negative of these terms or other comparable terminology. Any forward-looking statement speaks only as of the date of this presentation, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payers, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors', payers', and other contract counterparties' information systems; the outcome of litigation; quality performance and ratings; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company's website at http://investors.ehab.com.

**Investor relations contact**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

*Bob Okunski*

*investorrelations@ehab.com*

*469-860-6061*

**Media contact**

*Erin Volbeda* 

*media@ehab.com*

*972-338-5141*

## Exhibit 99.2

![](enhabit_earningsxslidesx001.jpg)

Second Quarter Earnings Call Supplemental Information August 6, 2025

------

![](enhabit_earningsxslidesx002.jpg)

Enhabit Home Health & Hospice 2 Disclaimer Forward looking statements This presentation contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, our future financial performance, our projected business results, or our projected capital expenditures. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "targets," "potential," or "continue" or the negative of these terms or other comparable terminology. Any forward-looking statement speaks only as of the date of this presentation, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payers, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors', payers', and other contract counterparties' information systems; the outcome of litigation; quality performance and ratings; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this presentation are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company's website at http://investors.ehab.com. Note regarding presentation of non-GAAP financial measures This presentation includes certain "non-GAAP financial measures" as defined in Regulation G under the Exchange Act, including Adjusted EBITDA, Adjusted EBITDA margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA margin, Adjusted earnings per share, and Adjusted free cash flow. For 2025, the Company has modified its methodology of calculating Adjusted free cash flow to exclude the impact of unusual or nonrecurring items on cash income taxes and changes in working capital. The change was made to conform to the Adjusted free cash flow measure with the current definition used by management and the Board of Directors to manage cash flow and evaluate performance. Prior periods presented herein have been recast to conform with the new methodology. The Company believes the non-GAAP financial measures are useful to investors because they facilitate evaluation of core business operating results over multiple periods unaffected by differences in unusual or nonrecurring items. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP are presented at the end of this presentation. Our Form 8-K, filed with the SEC as of the date of this presentation, provides further explanation and disclosure regarding Enhabit's use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Additionally, our Form 10-Q for the three months ended June 30, 2025, provides further information regarding "unusual or nonrecurring items that are not typical of ongoing operations," a reconciliation item in our Adjusted EBITDA calculation. Note regarding presentation of same-store comparisons The Company uses "same-store" comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

------

![](enhabit_earningsxslidesx003.jpg)

Contents Overview 4 2025 Priorities for Success 5 Quarterly Results at a Glance 6 Consolidated Results 7 Clinical Expertise and High-Quality Outcomes 8 Home Health Segment KPI Performance 9-10 Hospice Segment KPI Performance 11-12 Consolidated Adjusted EBITDA 13 Debt and Liquidity Metrics 14 Guidance 15 Adjusted Free Cash Flow Assumptions and Uses of Free Cash Flow 16 Appendix A: Supplemental Financial and Operational Metrics 17-26 Appendix B: Reconciliations to GAAP 27-33

------

![](enhabit_earningsxslidesx004.jpg)

Enhabit Home Health & Hospice 4 Overview 108 Hospice locations co-located with Home Health locations(1) Home Health Locations Hospice Locations Home Health & Hospice State Home Health Only State (1) As of June 30, 2025 - due to scale, not all locations can be represented by locational markers 114 Hospice locations(1) 249 Home Health locations(1) We are a leading provider of home health and hospice services that strives to provide superior, cost-effective care where patients prefer it: in their homes For over 25 years, we've provided care with high-quality outcomes becoming a trusted partner of health systems, payers and other risk-bearing entities We operate nationally across 34 states with approximately 10,600 employees We foster an award-winning culture that is a strategic advantage in attracting and retaining talent and a main contributor to our continued success 4 Home Health (1) and Hospice (3) de novo locations opened in 2025 Hospice Only State

------

![](enhabit_earningsxslidesx005.jpg)

Enhabit Home Health & Hospice 5 2025 Priorities for Success • Home health momentum delivered 2nd quarter of sequential growth in net service revenue and Adjusted EBITDA, while continuing to stabilize Medicare ADC. • Hospice consistent growth with 6th straight quarter of sequential ADC growth; double digit growth to prior year. • Home health successfully re- negotiated a national payer agreement resulting in a low double digit % rate increase. • De novo growth with 3 new de novo sites in Q2, bringing year to date total to 4 and on track to deliver goal of 10 in 2025. • Consistent de-levering with 5th straight quarter of debt prepayments, totaling $45M since Q1 '24, lowering interest expense by $3.2M over the same period. • Home health census ◦ Payer mix • Hospice average daily census • Open de novo locations in strategic markets • Optimize de novo locations opened in 2023 and 2024 • Continue de- leveraging the balance sheet • G&A expense management • Home health and Hospice cost per patient day • Home health revenue per patient day • Value-based performance • Patient and family experience • Home health hospital readmission rates • Hospice visits in the last days of life • Engagement • Retention • Business development direct selling headcount • Leadership development Strategy Execution Q2 2025 Highlights Growth Financial Health Quality People Reconciliations to GAAP provided in Appendix B

------

![](enhabit_earningsxslidesx006.jpg)

Enhabit Home Health & Hospice 6 Improved financial performance • Net income attributable to Enhabit, Inc. of $5.2 million. • Net service revenue grew 2.1% year over year and 2.4% sequentially to $266.1 million. • Adjusted EBITDA grew 6.7% year over year and 1.2% sequentially to $26.9 million. • Reduced bank debt by $10.0 million in Q2; bank debt lower $70.0 million from Q1 2024. Reconciliations to GAAP provided in Appendix B Quarterly Results at a Glance Non-Medicare admissions increased 5.2% • Total admissions growth of 1.3% year over year, 2.0% when normalized for branches closed in 2025. • Total ADC growth of 0.5% year over year and sequential growth of 2.1%. • Net service revenue grew 2.6% sequentially to $205.9 million. • Cost per patient day remained flat year over year with staffing optimization offsetting market inflation. Average daily census grew 12.3% year over year • ADC has increased sequentially every quarter since Q1 2024. • Admissions increased 8.7% year over year, 10.0% when normalized for branches closed in 2025. • Adjusted EBITDA increased 53.8% year over year. • Cost per patient day increased 1.0% year over year. Home Health Hospice Consolidated

------

![](enhabit_earningsxslidesx007.jpg)

Enhabit Home Health & Hospice 7 Consolidated Results Q2 '25 vs. '24($ in millions, except per share data) 2025 2024 Home health net service revenue $205.9 $210.2 (2.0) % Hospice net service revenue 60.2 50.4 19.4 % Total net service revenue $266.1 $260.6 2.1 % % of revenue % of revenue Cost of service 50.9 % $135.5 50.6 % $131.8 2.8 % Gross margin 49.1 % 130.6 49.4 % 128.8 1.4 % General and administrative expenses 38.8 % 103.2 39.5 % 103.0 0.2 % Total operating expenses 89.7 % $238.7 90.1 % $234.8 1.7 % Net income attributable to noncontrolling interests 0.5 0.6 Adjusted EBITDA(1) $26.9 $25.2 6.7 % Adjusted EBITDA margin(1) 10.1 % 9.7 % Net income (loss) attributable to Enhabit, Inc. $5.2 $(0.2) 2,700.0 % Reported diluted EPS $0.10 $— N/A Adjusted diluted EPS(1) $0.13 $0.07 85.7 % General and administrative expenses in the above table exclude: Stock-based compensation expense $3.6 $2.2 Unusual or nonrecurring items that are not typical of ongoing operations(2) $1.4 $4.8 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non- shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

------

![](enhabit_earningsxslidesx008.jpg)

Enhabit Home Health & Hospice 8 Clinical Expertise and High-Quality Outcomes Enhabit National Average % Better Than Average QoPC Star Rating1 3.1 3.0 3.3% 67% of our home health agencies are 3 Stars or higher; 21% are 4 Stars or higher1 HHCAHPS Star Rating2 4.0 3.7 8.1% 99% of our home health agencies are 3 Stars or higher; 80% are 4 Stars or higher2 30-Day Hospital Readmission Rate3 14.1% 18.0% 21.7% % of patients readmitted to an acute care hospital within 30 days of start of care or resumption of care Patient Visits in Last Days of Life4 67.1% 47.4% 41.6% % of patients who received in person visits from RN or medical social worker on at least two out of the final three days of the patient's life Standardized Protocols Motivated Clinicians Disciplined Use of Technology Superior Performance ü ü ü ü (1) Quality of Patient Care (QoPC) Star Ratings as of July 16, 2025 with claims data January 1, 2021 through December 31, 2023 and oasis-based data October 1, 2023 through September 30, 2024 (2) Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Patient Survey Star Ratings as of July 16, 2025 for dates of service January 1 to December 31, 2024 (3) Research Institute for Home Care 2024 Chartbook (data from Medicare Standard Analytics Files for CY 2023), Enhabit data is as of Q2 2025 (4) Medicare fee for service claims data from January 1, 2022 to December 31, 2023 (source Medicare Provider Data catalog - February 2025)

------

![](enhabit_earningsxslidesx009.jpg)

Enhabit Home Health & Hospice 9 Home Health Q2 Revenue KPI Performance Growth combined with continued focus on healthy payer mix as Payer Innovation strategy continues to set the stage to both stabilize absolute Medicare volume decline and grow Payer Innovation volumes. Successful execution on strategy to stem Medicare ADC rate of decline by more than half with Medicare ADC lower by 3.4% in the quarter vs. prior year; compared to a 14.1% decline in the corresponding 2024 period. Home health net service revenue increased 2.6% sequentially, while decreasing $(4.3) million, or (2.0)%, year over year. Highest revenue since Q3 of 2024 and sequential growth that sets the stage for incremental growth to prior year in 2H 2025. Q2 home health sequential revenue drivers: • Volume: increase in average daily census of 2.1% sequentially. • Calendar days: one additional calendar day 1.1% sequentially. • Unit revenue: decrease in revenue per patient day of (0.7)% sequentially. ADC growth to prior year of 0.5% on admissions growth of 1.3% partially offset by lower recertification volumes. Total ADC sequential improvement of 2.1% reflects the second straight quarter of sequential growth with recertification volumes improving 5.3%.

------

![](enhabit_earningsxslidesx010.jpg)

Enhabit Home Health & Hospice 10 Home Health Q2 Profitability KPI Performance Gross margin of 47.9% lower sequentially and year over year primarily on lower unit revenues. Q2 home health sequential gross margin drivers: • Unit Revenue: lower sequentially (0.7)% on lower Medicare volumes partially offset by other Payer Innovation contract growth. • Unit Cost: increased sequentially 0.4%. Reconciliations to GAAP provided in Appendix B Q2 home health Adjusted EBITDA of $39.3 million improved $1.0 million, or 2.6%, sequentially. Sequential Adjusted EBITDA variance drivers: • Volume improved Adjusted EBITDA $3.1 million on higher average daily census and one additional calendar day in the quarter. • Rate/Yield decreased Adjusted EBITDA $(1.5) million with gross margin as a % of revenue lower 60 bps on improved cost per patient day offset by lower unit revenue. • Sales and Ops back-office G&A costs decreased Adjusted EBITDA $(0.6) million primarily on increased sales-related costs to support volume growth. Cost per patient day flat to prior year with improved clinical staff productivity on improved volumes offsetting market inflation related impacts.

------

![](enhabit_earningsxslidesx011.jpg)

Enhabit Home Health & Hospice 11 Hospice Q2 Revenue KPI Performance Revenue per patient day improved 6.3% year over year and decreased (3.2)% sequentially primarily related to cap liability benefit in Q1. Continued strong growth momentum in the quarter with ADC increasing 3.7% sequentially and 12.3% to prior year. Admissions growth 8.7% year over year, with discharged average length of stay lower year over year. ADC growth every quarter since Q1 2024. Hospice net service revenue increased $9.8 million, or 19.4%, year over year and $0.9 million, or 1.5%, sequentially. Q2 hospice revenue drivers year over year: • Volume: increase in average daily census of 12.3% year over year. • Unit revenue: increase in revenue per patient day of 6.3% year over year.

------

![](enhabit_earningsxslidesx012.jpg)

Enhabit Home Health & Hospice 12 Hospice Q2 Profitability KPI Performance Gross margin of 53.0% increasing 240 bps year over year and lower (180) bps sequentially. Q2 hospice year over year revenue drivers: • Unit Revenue: increased 6.3% year over year primarily CMS rate increase and cap related benefits. • Unit Cost: increased 1.0% year over year on merit / market increases offset by improved clinical productivity. Hospice Adjusted EBITDA of $14.0 million increased $4.9 million, or 53.8%, year over year and lower $(1.0) million or (6.7)% sequentially. Year over Year Adjusted EBITDA variance drivers: • Volume increased Adjusted EBITDA $3.5 million on growth in ADC of 12.3%. • Rate/Yield increased Adjusted EBITDA $2.8 million with higher unit revenue per patient day somewhat offset by higher unit costs. • Sales and Ops back-office G&A costs decreased Adjusted EBITDA $(1.4) million to support growth. Cost per patient day of $78.7 only up 1.0% year over year as improved clinical productivity offset market- related inflation impacts. Reconciliations to GAAP provided in Appendix B

------

![](enhabit_earningsxslidesx013.jpg)

Enhabit Home Health & Hospice 13 Consolidated Adjusted EBITDA ($ in millions) Q2 2025 % of Consolidated Revenue Q2 2024 % of Consolidated Revenue Home health segment Adjusted EBITDA(1) $39.3 $44.2 Hospice segment Adjusted EBITDA(1) 14.0 9.1 Home office general and administrative expenses (26.4) 9.9% (28.1) 10.8% Consolidated Adjusted EBITDA(1) $26.9 $25.2 Home office general and administrative expenses in the above table exclude: Stock-based compensation $3.6 $2.2 Unusual or nonrecurring items that are not typical of ongoing operations(2) $1.4 $4.8 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Unusual or nonrecurring items in the three months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non- shareholder matters; in the three months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

------

![](enhabit_earningsxslidesx014.jpg)

Enhabit Home Health & Hospice 14 Debt & Liquidity Metrics ($ in millions) June 30, 2025 December 31, 2024 $400 million term loan facility, due 2027(1)(2) $338.3 $348.0 Advances under revolving credit facility, due 2027(1) 135.0 160.0 Finance lease obligations 6.0 7.4 Total debt $479.3 $515.4 Less: Cash and cash equivalents 37.1 28.4 Net debt $442.2 $487.0 Net debt to Adjusted EBITDA(3) 4.3x 4.9x Trailing twelve-month Adjusted EBITDA(4) $103.1 $100.1 Available liquidity(5) $113.5 $79.8 (1) The Q2 2025 weighted average interest rate was 6.7% (SOFR + credit spread adjustment + 250 bps). (2) In October 2022, Enhabit entered into an interest rate swap to fix the rate on $200 million of its term loan. The swap fixes the SOFR component of the interest rate at 4.3%, and matures in October 2025. (3) Defined as the ratio of Net debt to Trailing twelve-month Adjusted EBITDA. (4) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (5) Defined as of June 30, 2025 as our $220.0 million revolving credit facility, less $135.0 million in advances, less $8.6 million in standby letters of credit plus cash and cash equivalents of $37.1 million, and as of December 31, 2024 as our $220.0 million revolving credit facility, less $160.0 million in advances, less $8.6 million in standby letters of credit plus cash and cash equivalents of $28.4 million.

------

![](enhabit_earningsxslidesx015.jpg)

Enhabit Home Health & Hospice 15 2025 Guidance ($ in millions, except per share data) 2024 Actuals(1) 2025 Previous Guidance 2025 Updated Guidance Net service revenue $1,034.8 $1,050 to $1,080 $1,060 to $1,073 Adjusted EBITDA $100.1 $101 to $107 $104 to $108 Adjusted EPS $0.21 $0.41 to $0.51 $0.47 to $0.55 Guidance considerations Tax rate: approximately 24% Diluted share count: approximately 51.2 million shares Home health considerations Volume (ADC): increase of 2.0% to 3.0% Unit revenue (per patient day): decrease of (2.7)% to (2.3)% Cost per day: decrease of (1.0)% to (1.5)% Other: continued shift to more non-Medicare admissions Hospice considerations Volume (ADC): increase of 10.9% to 11.6% Unit revenue (per patient day): increase of 4.9% to 5.3% Cost per patient day: increase of 1.0% to 0.6% (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. Updated as of August 6, 2025

------

![](enhabit_earningsxslidesx016.jpg)

Enhabit Home Health & Hospice 16 Adjusted Free Cash Flow Assumptions ($ in millions) Certain cash flow items 2024 Full Year 2025 YTD 2025 Prior Assumptions 2025 Assumptions Adjusted EBITDA(1) $100.1 $53.5 $101 to $107 $104 to $108 Less: Cash interest expense(2) 42.7 17.4 $37 to $39 $32 to $33 Cash income tax payments, net(3)(4) 1.9 0.6 $7 to $8 $3 to $4 Working capital and other(4) (1.8) 5.5 $0 to $2 $12 to $15 Maintenance capital expenditures 3.8 2.2 $4 to $6 $4 to $5 Adjusted free cash flow $53.5 $27.8 $47 to $58 $47 to $57 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Cash interest payments in 2025 are based on current interest rate forward curves. (3) Enhabit expects to become a cash taxpayer in 2025. (4) For 2025 and going forward, adjusted free cash flow will exclude the cash impact of unusual and nonrecurring items from both cash income tax payments (refunds), net, and working capital and other. The 2024 calculations have been conformed to the current methodology, which has an impact of $(1.9) million and less than $0.1 million for Q2 and the full year, respectively. ($ in millions) Growth in Core Business 2024 Full Year YTD 2025 2025 Assumptions De novos $1.2 $0.3 $2.5 to $3.0 Acquisitions $— $— TBD Debt repayments, net $40.0 $35.0 TBD Adjusted Free Cash Flow Uses and Use Assumptions

------

![](enhabit_earningsxslidesx017.jpg)

Enhabit Home Health & Hospice 17 Appendix A

------

![](enhabit_earningsxslidesx018.jpg)

Enhabit Home Health & Hospice 18 Home Health Segment ($ in millions) Q2 '25 vs. '242025 2024 Net service revenue: Medicare $116.0 $121.7 (4.7) % Non-Medicare 87.8 86.3 1.7 % Private duty(1) 2.1 2.2 (4.5) % Home health net service revenue 205.9 210.2 (2.0) % Cost of service 107.2 106.9 0.3 % Gross margin 47.9 % 49.1 % General and administrative expenses 59.1 58.6 0.9 % Net income attributable to noncontrolling interests 0.3 0.5 (40.0) % Segment Adjusted EBITDA(2) $39.3 $44.2 (11.1) % % Segment Adj. EBITDA margin(2) 19.1 % 21.0 % Operational metrics (actual amounts) Medicare: Admissions 23,138 24,015 (3.7) % Recertifications 15,860 16,639 (4.7) % Completed episodes 38,818 41,620 (6.7) % Average daily census 19,931 20,629 (3.4) % Visits 546,877 597,742 (8.5) % Visits per episode 14.1 14.4 (2.1) % Revenue per episode $2,988 $2,924 2.2 % Non-Medicare: Admissions 31,774 30,209 5.2 % Recertifications 14,532 14,587 (0.4) % Average daily census 22,191 21,282 4.3 % Visits 570,424 581,326 (1.9) % Total: Admissions 54,912 54,224 1.3 % Same-store total admissions growth 1.3 % Recertifications 30,392 31,226 (2.7) % Same-store total recertifications growth (2.7) % Average daily census 42,122 41,911 0.5 % Visits 1,117,301 1,179,068 (5.2) % Visits per episode 13.7 14.0 (2.1) % Cost per visit $94.7 $89.0 6.4 % Revenue per patient day $53.7 $55.1 (2.5) % Cost per patient day $28.0 $28.0 — % (1) Private duty represents long-term comprehensive hourly nursing medical care. (2) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx019.jpg)

Enhabit Home Health & Hospice 19 Home Health Operational Metrics (net service revenue $ in millions) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 YTD 2025 Medicare $128.3 $121.7 $117.3 $117.3 $484.6 $114.2 $116.0 $230.2 Non-Medicare 82.6 86.3 81.5 80.8 331.2 84.4 87.8 172.2 Private duty(1) 2.3 2.2 2.2 2.3 9.0 2.0 2.1 4.1 Home health net service revenue $213.2 $210.2 $201.0 $200.4 $824.8 $200.6 $205.9 $406.5 (actual amounts) Medicare: Admissions 25,944 24,015 23,422 23,121 96,502 24,044 23,138 47,182 Recertifications 17,652 16,639 16,101 16,300 66,692 15,734 15,860 31,594 Completed episodes 43,171 41,620 38,866 39,104 162,761 38,266 38,818 77,084 Average daily census 21,709 20,629 19,629 19,816 20,446 20,110 19,931 20,020 Visits 632,047 597,742 561,525 560,002 2,351,316 547,690 546,877 1,094,567 Visits per episode 14.6 14.4 14.4 14.3 14.4 14.3 14.1 14.2 Revenue per episode $2,972 $2,924 $3,018 $3,000 $2,977 $2,984 $2,988 $2,986 Non-Medicare: Admissions 30,881 30,209 29,950 29,810 120,850 33,178 31,774 64,952 Recertifications 13,489 14,587 14,112 13,541 55,729 13,133 14,532 27,665 Average daily census 20,541 21,282 20,358 19,967 20,537 21,126 22,191 21,661 Visits 571,289 581,326 552,815 533,618 2,239,048 542,526 570,424 1,112,950 Total: Admissions 56,825 54,224 53,372 52,931 217,352 57,222 54,912 112,134 Recertifications 31,141 31,226 30,213 29,841 122,421 28,867 30,392 59,259 Average daily census 42,250 41,911 39,987 39,783 40,983 41,236 42,122 41,682 Visits 1,203,336 1,179,068 1,114,340 1,093,620 4,590,364 1,090,216 1,117,301 2,207,517 Visits per episode 14.9 14.0 14.1 13.9 14.2 13.9 13.7 13.8 Cost per visit $90.0 $89.0 $94.0 $95.0 $93.0 $93.5 $94.7 $94.1 Revenue per patient day $55.5 $55.1 $54.6 $54.8 $55.0 $54.1 $53.7 $53.9 Cost per patient day $28.6 $28.0 $28.8 $28.8 $28.6 $27.9 $28.0 $27.9 (1) Private duty represents long-term comprehensive hourly nursing medical care.

------

![](enhabit_earningsxslidesx020.jpg)

Enhabit Home Health & Hospice 20 Hospice Segment ($ in millions) Q2 '25 vs. '242025 2024 Net service revenue $60.2 $50.4 19.4 % Cost of service 28.3 24.9 13.7 % Gross margin 53.0 % 50.6 % General and administrative expenses 17.7 16.3 8.6 % Net income attributable to noncontrolling interests 0.2 0.1 100.0 % Segment Adjusted EBITDA(1) $14.0 $9.1 53.8 % % Segment Adj. EBITDA margin(1) 23.3 % 18.1 % Operational metrics (actual amounts) Total admissions 3,140 2,888 8.7 % Same-store total admissions growth 6.2 % Patient days 359,486 320,026 12.3 % Discharged average length of stay 103 108 (4.6) % Average daily census 3,950 3,517 12.3 % Revenue per patient day $167.5 $157.5 6.3 % Cost per patient day $78.7 $77.9 1.0 % (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx021.jpg)

Enhabit Home Health & Hospice 21 Hospice Operational Metrics (net service revenue $ in millions) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 YTD 2025 Hospice net service revenue $49.2 $50.4 $52.6 $57.8 $210.0 $59.3 $60.2 $119.5 (actual amounts) Total admissions 3,032 2,888 3,046 3,059 12,025 3,274 3,140 6,414 Patient days 308,542 320,026 333,247 343,063 1,304,878 342,784 359,486 702,270 Discharged average length of stay 104 108 100 110 105 101 103 102 Average daily census 3,391 3,517 3,622 3,729 3,565 3,809 3,950 3,880 Revenue per patient day $159.6 $157.5 $157.7 $168.6 $160.9 $173.0 $167.5 $170.2 Cost per patient day $78.8 $77.9 $77.3 $80.4 $78.6 $78.2 $78.7 $78.5

------

![](enhabit_earningsxslidesx022.jpg)

Enhabit Home Health & Hospice 22 Consolidated Results – YTD 2025 Year-To-Date '25 vs. '24($ in millions, except per share data) 2025 2024 Home health net service revenue $406.5 $423.4 (4.0) % Hospice net service revenue 119.5 99.6 20.0 % Total net service revenue $526.0 $523.0 0.6 % % of Revenue % of Revenue Cost of service 50.5 % 265.7 50.9 % 266.0 (0.1) % Gross margin 49.5 % 260.3 49.1 % 257.0 1.3 % General and administrative expenses 39.1 % 205.7 39.2 % 205.2 0.2 % Total operating expenses 89.6 % 471.4 90.1 % 471.2 — % Net income attributable to noncontrolling interests 1.1 1.3 Adjusted EBITDA(1) $53.5 $50.5 5.9 % Adjusted EBITDA margin(1) 10.2 % 9.7 % Net income attributable to Enhabit, Inc. $23.0 $— N/A Reported diluted EPS $0.45 $— N/A Adjusted diluted EPS(1) $0.23 $0.14 64.3 % General and administrative expenses in the above table exclude: Gain on disposal of assets $— $(0.2) Stock-based compensation expense $7.6 $4.0 Unusual or nonrecurring items that are not typical of ongoing operations(2) $2.4 $8.5 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Unusual or nonrecurring items in 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

------

![](enhabit_earningsxslidesx023.jpg)

Enhabit Home Health & Hospice 23 Home Health Segment Results – YTD 2025 ($ in millions) Year-To-Date '25 vs. '242025 2024 Net service revenue: Medicare $230.2 $250.0 (7.9) % Non-Medicare 172.2 169.0 1.9 % Private duty(1) 4.1 4.4 (6.8) % Home health net service revenue 406.5 423.4 (4.0) % Cost of service 210.6 216.8 (2.9) % Gross margin 48.2 % 48.8 % General and administrative expenses 117.5 118.1 (0.5) % Net income attributable to noncontrolling interests 0.8 1.1 (27.3) % Segment Adjusted EBITDA(2) $77.6 $87.4 (11.2) % % Segment Adj. EBITDA margin(2) 19.1 % 20.6 % Operational metrics (actual amounts) Medicare: Admissions 47,182 49,959 (5.6) % Recertifications 31,594 34,291 (7.9) % Completed episodes 77,084 84,791 (9.1) % Average daily census 20,020 21,169 (5.4) % Visits 1,094,567 1,229,789 (11.0) % Visits per episode 14.2 14.5 (2.1) % Revenue per episode $2,986 $2,948 1.3 % Non-Medicare: Admissions 64,952 61,090 6.3 % Recertifications 27,665 28,076 (1.5) % Average daily census 21,661 20,911 3.6 % Visits 1,112,950 1,152,615 (3.4) % Total: Admissions 112,134 111,049 1.0 % Same-store total admissions growth 1.0 % Recertifications 59,259 62,367 (5.0) % Same-store total recertifications growth (5.0) % Average daily census 41,682 42,080 (0.9) % Visits 2,207,517 2,382,404 (7.3) % Visits per episode 13.8 14.5 (4.8) % Cost per visit $94.1 $89.6 5.0 % Revenue per patient day $53.9 $55.3 (2.5) % Cost per patient day $27.9 $28.3 (1.4) % (1) Private duty represents long-term comprehensive hourly nursing medical care. (2) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx024.jpg)

Enhabit Home Health & Hospice 24 Hospice Segment Results – YTD 2025 ($ in millions) Year-To-Date '25 vs. '242025 2024 Net service revenue $119.5 $99.6 20.0 % Cost of service 55.1 49.2 12.0 % Gross margin 53.9 % 50.6 % General and administrative expenses 35.1 32.0 9.7 % Net income attributable to noncontrolling interests 0.3 0.2 50.0 % Segment Adjusted EBITDA(1) $29.0 $18.2 59.3 % % Segment Adj. EBITDA margin(1) 24.3 % 18.3 % Operational metrics (actual amounts) Total admissions 6,414 5,920 8.3 % Same-store total admissions growth 5.7 % Patient days 702,270 628,568 11.7 % Discharged average length of stay 102 106 (3.8) % Average daily census 3,880 3,454 12.3 % Revenue per patient day $170.2 $158.5 7.4 % Cost per patient day $78.5 $78.3 0.3 % (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx025.jpg)

Enhabit Home Health & Hospice 25 Payer Sources As a % of Revenue Second Quarter Year-To-Date Fiscal Year Consolidated 2025 2024 2025 2024 2024 Medicare 66.0% 65.7% 66.0% 66.5% 66.8% Medicare Advantage 23.9% 23.5% 23.6% 23.1% 23.0% Managed Care 8.9% 9.6% 8.9% 9.3% 9.1% Medicaid 0.7% 1.0% 0.9% 0.9% 0.9% Other 0.5% 0.2% 0.6% 0.2% 0.2% Total 100.0% 100.0% 100.0% 100.0% 100.0% Home Health Medicare 56.3% 57.9% 56.6% 59.0% 58.8% Medicare Advantage 31.0% 29.2% 30.6% 28.5% 28.8% Managed Care 11.2% 11.5% 11.1% 11.0% 11.1% Medicaid 0.9% 1.1% 1.0% 1.2% 1.1% Other 0.6% 0.3% 0.7% 0.3% 0.2% Total 100.0% 100.0% 100.0% 100.0% 100.0% Hospice Medicare 99.2% 98.2% 97.9% 98.1% 98.3% Managed Care 0.8% 1.8% 1.4% 1.9% 1.7% Medicaid —% —% 0.6% —% —% Total 100.0% 100.0% 100.0% 100.0% 100.0%

------

![](enhabit_earningsxslidesx026.jpg)

Enhabit Home Health & Hospice 26 (1) MedPAC Report to Congress as of March 2023. (2) MedPAC Tab H Hospice December 2024 (3) MedPAC Tab G Home Health December 2024. (Calculated based on 30-day home health period.) (4) AARP 2024 Survey. (5) Centers for Medicare & Medicaid Services, Medicare Trustees' Report Nov 2021. Aging Population Cost Efficiency of Home Health Care Large and Growing Addressable Markets(5) Large and Growing Addressable Markets4 ~$41bn 2028 Medicare skilled home health expenditures ~$32bn 2028 Medicare Hospice expenditures 75% of those age 50 and over want to stay in their residence as they age(4) 10x lower cost than other care settings Post-Acute Service Sector Annual Medicare Spending Average Medicare Cost Per Day Skilled Nursing Facilities (SNF)(1) $27 billion $556 Hospice(2) $26 billion $186 Home Health(3) $16 billion $63 Home health = 76 Hospice = 83 Number of people age 65 or older, by age group (millions) ~5% expected growth in target population over the next three years3 We are here Avg. age of our patients Outlook: Attractive Industry Tailwinds Demographic Trends and Our Ability to Deliver Cost-Effective, High-Quality Care Supports Long-Term Growth

------

![](enhabit_earningsxslidesx027.jpg)

Enhabit Home Health & Hospice 27 Appendix B

------

![](enhabit_earningsxslidesx028.jpg)

Enhabit Home Health & Hospice 28 Reconciliation of Earnings Per Share to Adjusted Diluted Earnings Per Share (actual amounts) Q2 Year-To-Date 2025 2024 2025 2024 Earnings per common share: Diluted earnings per share attributable to Enhabit, Inc. common stockholders $0.10 $— $0.45 $— Gain on sale of investment and disposal of assets(1) — — (0.29) — Unusual or nonrecurring items that are not typical of ongoing operations(2) 0.02 0.07 0.04 0.13 Provision for incomes taxes(3) 0.01 — 0.04 0.01 Adjusted diluted earnings per share(4) $0.13 $0.07 $0.23 $0.14 (1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment. (2) Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation and the effect of a calculation allowance recorded against a portion of our deferred tax assets. (4) Adjusted diluted earnings per share may not sum due to rounding.

------

![](enhabit_earningsxslidesx029.jpg)

Enhabit Home Health & Hospice 29 Reconciliation of Net Income to Adjusted EBITDA ($ in millions) Q2 Year-To-Date 2025 2024 2025 2024 Net income $5.7 $0.4 $24.1 $1.3 Interest expense and amortization of debt discounts and fees 8.7 10.9 18.1 22.0 Provision for (benefit from) income taxes 2.3 (0.1) 9.7 0.8 Depreciation and amortization 5.7 7.6 12.0 15.4 Gain on sale of investment and disposal of assets(1) — — (19.3) (0.2) Stock-based compensation 3.6 2.2 7.6 4.0 Net income attributable to noncontrolling interests (0.5) (0.6) (1.1) (1.3) Unusual or nonrecurring items that are not typical of ongoing operations(2) 1.4 4.8 2.4 8.5 Adjusted EBITDA $26.9 $25.2 $53.5 $50.5 (1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment. (2) Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder and non-shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

------

![](enhabit_earningsxslidesx030.jpg)

Enhabit Home Health & Hospice 30 Q2 Year-To-Date ($ in millions) 2025 2024 2025 2024 Income before income taxes and noncontrolling interests $8.0 $0.3 $33.8 $2.1 Non-segment general and administrative expenses 27.8 32.9 55.5 63.4 Interest expense and amortization of debt discounts and fees 8.7 10.9 18.1 22.0 Depreciation and amortization 5.7 7.6 12.0 15.4 Gain on sale of investment(1) — — (19.3) — Stock-based compensation 3.6 2.2 7.6 4.0 Net income attributable to noncontrolling interests (0.5) (0.6) (1.1) (1.3) Total Segment Adjusted EBITDA $53.3 $53.3 $106.6 $105.6 Home Health Hospice Home Health Hospice Q2 Q2 Year-To-Date Year-To-Date ($ in millions) 2025 2024 2025 2024 2025 2024 2025 2024 Net service revenue $205.9 $210.2 $60.2 $50.4 $406.5 $423.4 $119.5 $99.6 Labor 98.1 97.3 17.6 15.5 192.4 197.1 34.4 30.7 Supplies and pharmacy 2.4 2.3 5.4 4.7 4.8 5.1 10.6 9.3 Travel 5.2 5.5 1.2 1.2 10.3 11.1 2.4 2.3 Other cost of service 1.5 1.8 4.1 3.5 3.1 3.5 7.7 6.9 Total cost of service, excluding deprecation and amortization 107.2 106.9 28.3 24.9 210.6 216.8 55.1 49.2 General and administrative expenses 46.8 47.7 14.5 13.3 93.5 96.4 28.6 26.2 Other general and administrative expenses 12.3 10.9 3.2 3.0 24.0 21.7 6.5 5.8 Total general and administrative expenses 59.1 58.6 17.7 16.3 117.5 118.1 35.1 32.0 Net income attributable to noncontrolling interests 0.3 0.5 0.2 0.1 0.8 1.1 0.3 0.2 Segment Adjusted EBITDA $39.3 $44.2 $14.0 $9.1 $77.6 $87.4 $29.0 $18.2 Segment Adjusted EBITDA margin(2) 19.1 % 21.0 % 23.3 % 18.1 % 19.1 % 20.6 % 24.3 % 18.3 % (1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment. (2) Segment Adjusted EBITDA margin is defined as the ratio of Segment Adjusted EBITDA to net service revenue. Reconciliation of Income Before Income Taxes And Noncontrolling Interests to Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin

------

![](enhabit_earningsxslidesx031.jpg)

Enhabit Home Health & Hospice 31 Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow ($ in millions) Q2 Year-To-Date 2025 2024 2025 2024 Net cash provided by operating activities $10.6 $9.6 $28.5 $26.9 Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.4 4.8 4.4 8.5 Capital expenditures for maintenance (1.9) (0.7) (2.2) (2.5) Other working capital adjustments(2) (1.1) (3.0) (1.9) (3.6) Distributions paid to noncontrolling interests of consolidated affiliates (0.1) (2.2) (1.0) (2.2) Adjusted free cash flow $10.9 $8.5 $27.8 $27.1 (1) Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation, and third-party legal and advisory fees related to shareholder and non- shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation. (2) For 2025 and going forward, adjusted free cash flow will exclude the cash impact of unusual and nonrecurring items from both cash income tax payments (refunds), net and working capital and other. The 2024 calculations have been conformed to the current methodology, which has an impact of $(1.9) million for both Q2 and the year to date period.

------

![](enhabit_earningsxslidesx032.jpg)

Enhabit Home Health & Hospice 32 Reconciliation of Gross Margin to Adjusted EBITDA Margin Q2 Year-To-Date 2025 2024 2025 2024 Gross margin as a percentage of revenue 49.1 % 49.4 % 49.5 % 49.1 % General and administrative expenses (40.7) % (42.2) % (41.0) % (41.6) % Stock-based compensation 1.4 % 0.9 % 1.4 % 0.8 % Noncontrolling interests (0.2) % (0.2) % (0.2) % (0.2) % Unusual or nonrecurring items that are not typical of ongoing operations(1) 0.5 % 1.8 % 0.5 % 1.6 % Adjusted EBITDA margin 10.1 % 9.7 % 10.2 % 9.7 % (1) Unusual or nonrecurring items in the three and six months ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder and non- shareholder matters; in the three and six months ended June 30, 2024, they include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

------

![](enhabit_earningsxslidesx033.jpg)

Enhabit Home Health & Hospice 33 Reconciliation of Net Income (Loss) to Trailing Twelve-Month Adjusted EBITDA ($ in millions) Quarter Ended Trailing Twelve Months Ended September 30, December 31, March 31, June 30, June 30, December 31, 2024 2024 2025 2025 2025 2024 Net income (loss) $(109.5) $(45.8) $18.4 $5.7 $(131.2) $(154.0) Interest expense and amortization of debt discounts and fees 10.8 10.1 9.4 8.7 39.0 42.9 Provision for (benefit from) income taxes 0.7 (5.5) 7.4 2.3 4.9 (4.0) Depreciation and amortization 8.2 7.9 6.3 5.7 28.1 31.5 Gain on sale of investment and disposal of assets(1) (0.3) (0.2) (19.3) — (19.8) (0.7) Impairment of goodwill 107.9 53.8 — — 161.7 161.7 Stock-based compensation 3.8 3.9 4.0 3.6 15.3 11.7 Net income attributable to noncontrolling interests (0.7) (0.2) (0.6) (0.5) (2.0) (2.2) Unusual or nonrecurring items that are not typical of ongoing operations(2)(3)(4)(5)(6) 3.6 1.1 1.0 1.4 7.1 13.2 Adjusted EBITDA $24.5 $25.1 $26.6 $26.9 $103.1 $100.1 (1) Gain on sale of investment in the three months ended March 31, 2025 resulted from the sale of Medalogix investment. (2) Unusual or nonrecurring items in the quarter ended September 30, 2024 include costs associated with shareholder activism and restructuring activities and severance. (3) Unusual or nonrecurring items in the quarter ended December 31, 2024 include costs associated with nonroutine litigation and severance. (4) Unusual or nonrecurring items in the quarter ended March 31, 2025 include was costs associated with restructuring activities and severance and nonroutine litigation. (5) Unusual or nonrecurring items in the quarter ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder and non-shareholder matters. (6) Unusual or nonrecurring items in the year ended December 31, 2024 also include costs associated with shareholder activism, the strategic review process, nonroutine litigation, restructuring activities and severance.

------